Short Interest in Capricor Therapeutics Inc (NASDAQ:CAPR) Declines By 27.1%

Capricor Therapeutics Inc (NASDAQ:CAPR) was the recipient of a large decline in short interest in November. As of November 15th, there was short interest totalling 3,850,000 shares, a decline of 27.1% from the October 31st total of 5,280,000 shares. Based on an average trading volume of 3,160,000 shares, the short-interest ratio is presently 1.2 days.

Capricor Therapeutics Stock Performance

CAPR traded down $0.03 during trading on Friday, reaching $19.01. 571,850 shares of the company’s stock were exchanged, compared to its average volume of 1,108,092. The company’s fifty day simple moving average is $18.03 and its 200-day simple moving average is $9.41. Capricor Therapeutics has a 1 year low of $2.90 and a 1 year high of $23.40.

Analysts Set New Price Targets

CAPR has been the subject of several analyst reports. Oppenheimer reiterated an “outperform” rating and set a $15.00 price objective on shares of Capricor Therapeutics in a report on Monday, September 23rd. Cantor Fitzgerald increased their price target on Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. Maxim Group boosted their price target on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. Piper Sandler initiated coverage on shares of Capricor Therapeutics in a research report on Monday, October 21st. They issued an “overweight” rating and a $35.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $77.00 target price on shares of Capricor Therapeutics in a research note on Thursday, November 14th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Capricor Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $34.50.

Insider Transactions at Capricor Therapeutics

In other news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the firm’s stock in a transaction that occurred on Friday, September 20th. The stock was bought at an average price of $5.36 per share, with a total value of $14,999,997.52. Following the completion of the transaction, the insider now directly owns 7,090,351 shares of the company’s stock, valued at approximately $38,004,281.36. The trade was a 65.21 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 12.00% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CAPR. Main Street Financial Solutions LLC grew its stake in shares of Capricor Therapeutics by 37.5% during the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after purchasing an additional 7,500 shares during the period. SG Americas Securities LLC purchased a new position in Capricor Therapeutics in the third quarter valued at $133,000. Bank of New York Mellon Corp increased its holdings in Capricor Therapeutics by 12.8% in the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after buying an additional 9,040 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in shares of Capricor Therapeutics in the third quarter worth about $161,000. Finally, Sassicaia Capital Advisers LLC purchased a new stake in shares of Capricor Therapeutics during the 3rd quarter worth about $192,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.